Marker Therapeutics is trading 5.7% down at $1.33 amid ongoing volatility and profit-taking following a sharp multi-month run-up driven by positive MT-601/APOLLO trial data.
- The move appears tied to broader weakness in biotech sentiment and technical Strong Sell signals, as there have been no new company-specific announcements today.
- Investors continue to weigh persistent going-concern and cash-burn risks that were highlighted in the company's recent financial filings and analysis.